162787-61-3

Basic information

• Product Name: 2-METHANESULFONYLAMINO-BENZOIC ACID
• Synonyms: 2-METHANESULFONYLAMINO-BENZOIC ACID;2-[(METHYLSULFONYL)AMINO]BENZOIC ACID;2-(Methanesulfonylamino)benzoic acid, min. 95 %;2-(Methylsulfonamido)benzoic acid;2-MethanesulfonaMidobenzoic acid;2-[(Methylsulphonyl)amino]benzoicacid97%
• CAS NO: 162787-61-3
• Molecular Formula: C₈H₉NO₄S
• Molecular Weight: 215.23
• Mol File: 162787-61-3.mol

Chemical Properties

• Melting Point: 187-189 °C
• Boiling Point: 397.6°C at 760 mmHg
• Flash Point: 194.3°C
• Appearance: /
• Density: 1.51g/cm³
• Vapor Pressure: 4.9E-07mmHg at 25°C
• Refractive Index: 1.621
• Storage Temp.: 2-8°C
• PKA: 3.17±0.36(Predicted)
• CAS DataBase Reference: 2-METHANESULFONYLAMINO-BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-METHANESULFONYLAMINO-BENZOIC ACID(162787-61-3)
• EPA Substance Registry System: 2-METHANESULFONYLAMINO-BENZOIC ACID(162787-61-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• HazardClass: IRRITANT
• Hazardous Substances Data: 162787-61-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Methanesulfonylamino-benzoic acid is used as an anti-inflammatory medication for the treatment of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. It is effective in reducing inflammation in the digestive tract and may help prevent the relapse of these conditions.
Used in Gastroenterology:
2-Methanesulfonylamino-benzoic acid is used as a therapeutic agent in gastroenterology to manage the symptoms and progression of ulcerative colitis and Crohn's disease. Its local anti-inflammatory action in the colon helps alleviate the discomfort and complications associated with these conditions.
Available in various forms, 2-Methanesulfonylamino-benzoic acid can be administered through oral tablets, capsules, and rectal suppositories, providing flexibility in treatment options. However, it is crucial to consult with a healthcare professional before using this medication, as it may interact with other drugs and pose potential risks for certain individuals.

InChI:InChI=1/C8H9NO4S/c1-14(12,13)9-7-5-3-2-4-6(7)8(10)11/h2-5,9H,1H3,(H,10,11)

Upstream product

• 87-25-2 2-ethoxycarbonylaniline 
• 98-88-4 benzoyl chloride 
• 65-85-0 benzoic acid 
• 134-20-3 2-carbomethoxyaniline 
• 716-41-6 methyl N-mesylanthranilate 
• 91013-48-8 2-methanesulfonylaminobenzoic acid ethyl ester 
• 118-92-3 anthranilic acid 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 934421-03-1 N-(butylcarbamoyl-phenyl-methyl)-N-(2-hydroxy-ethyl)-2-methanesulfonylamino-benzamide 
• 1025713-51-2 1-(2-methanesulfonylamino-benzoyl)-piperidine-3-carboxylic acid ethyl ester 
• 934421-05-3 N-(cyclohexylcarbamoyl-furan-2-yl-methyl)-N-(2-hydroxy-ethyl)-2-methanesulfonylamino-benzamide 
• 14107-94-9 o-Methansulfonamido-benzoesaeure-p-nitrophenylester 
• 934421-00-8 N-[benzylcarbamoyl-(3-bromo-phenyl)-methyl]-N-(2-hydroxy-ethyl)-2-methanesulfonylamino-benzamide 
• 1353623-05-8 (S)-N-(2-(2-(5,6-dimethylpyrazolo[1,5-a]pyrimidin-2-yl)-piperidine-1-carbonyl)phenyl)methanesulfonamide 
• 1353623-10-5 (S)-N-(2-(2-(5,6,7-trimethylpyrazolo[1,5-a]pyrimidin-2-yl)piperidine-1-carbonyl)phenyl)methanesulfonamide 
• 1429226-58-3 C₁₇H₁₇N₃O₅S₂ 
• 1361013-12-8 C₂₄H₂₀N₄O₄S 
• 1361013-34-4 C₂₂H₁₈N₄O₃S 
• 1361013-33-3 C₁₅H₁₂N₂O₄S 
• 1353623-11-6 (S)-N-(2-(2-(5,6-dimethyl-7-(methylamino)pyrazolo[1,5-a]-pyrimidin-2-yl)piperidine-1-carbonyl)phenyl)methanesulfonamide 

Relevant articles and documents

2-Aminophenyl-1H-pyrazole as a Removable Directing Group for Copper-Mediated C-H Amidation and Sulfonamidation

2-Aminophenyl-1H-pyrazole was discovered as a removable bidentate directing group for copper-mediated aerobic oxidative C(sp2-H) bond amidation and sulfonamidation. When Cu(OAc)2 was employed as the copper source and 1,1,3,3-tetramet

Synthesis, characterization and biological activities of 2-[(methyl sulfonyl)]amino benzoic acid derivatives and their metal complexes

Sulfonamide derivatives and their metal complexes are acknowledged pharmaceutical moieties because this group has been played the key role as a functional part of the most of the drug structures due to constancy and for bearance in human beings. Sulfonamides have endowed great biological potential such as antibacterial, insulin releasing, carbonic anhydrase inhibitory, anti-inflammatory, antifungal and antitumor activities. In the present work, 2-[(methyl sulfonyl)] amino benzoic acid was N-alkylated using alkylating agent such as methyl. Due to the presence of electron donating groups like, -COOH, -SO2, N-, the above mentioned molecules act as an excellent chelating agent. These substituted N-alkylated sulfonamide ligands were treated with a number of outer and inner transition metals such as Co(II), Cu(II), Ce(II), Pr(II), Dy(II) and Nd(II) to form coordinate complexes. These newly synthesized sulfonamides and their metal complexes were characterized by melting points, solubility, colour, FTIR analysis and XRD. These products were subjected for antimicrobial activities as well as other accessible applications.

The effect of hydrogen bond on Br?nsted acid-catalyzed intramolecular hydroamination of unfunctionalized olefins

The catalytic activity of benzoic acid could be increased by introducing a hydrogen bond donor group at the ortho-position. Preliminary DFT calculation indicated that the activation of CC double bond was realized by the action of both the carboxyl group and the hydrogen bond donor. The amino group was brought to the activated CC bond by the interaction between the carboxyl oxygen and amino proton. This interaction also increased the nucleophilicity of the amino group. Thus, in the presence of 20 mol % of 2-(trifluoromethanesulfonamido)benzoic acid, intramolecular hydroamination of unfunctionalized olefins gave the corresponding products in up to 95% isolated yields.

The ant-pro reverse-turn motif. Structural features and conformational characteristics

This article details the characteristic conformational features of the Ant-Pro reverse turn - a folded pseudo β-turn motif that displays a closed nine-membered-ring hydrogen-bonded network involving just two amino acid residues, namely anthranilic acid (A

TRIAZINE-BASED COMPOUND AND ULTRAVIOLET ABSORBER

A compound represented by the following formula (1): wherein each of R1b, R1c, R1d, R1g, R1h, R1i, R1k, R1m, R1n and R1p independently represents a hydrogen atom or a monovalent substituent, the monovalent substituents may combine with each other to form a ring, provided that at least one of R1c and R1h represents a hydrogen atom or a substituent having a positive σp value of the Hammett's rule, each of R1a, R1e, R1f and R1j independently represents a hydrogen atom or a monovalent substituent excluding —NHY1 and —OH, Y1 represents —COR1q or —SO2R1r, and each of R1q and R1r independently represents a monovalent substituent.

NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, METHODS OF USE FOR SAME, AND METHODS FOR PREPARING SAME

The present invention relates to a novel class of compounds comprising formula I, wherein n is 0 or 1. A is NR1, O, or S, wherein R1 is H, hydroxyl, C1-C10 alkyl, C1-C10 alkoxy, alkenyl, aryl, alkylaryl or arylalkyl. X is a carboxylate, a phosphonate, or a phosphate residue, or a C1-C10 alkyl residue optionally substituted with a carboxylate, phosphonate or phosphate residue. Y is a C1-C20 alkyl, alkenyl, halide, hydroxyl, C1-C20 alkoxy, aryl, alkylaryl, arylalkyl, cycloalkyl, cycloalkenyl, or a heterocyclic ring and is optionally substituted with one or more halides. Z is a H, a hydroxyl group, a halide, an aryl group, an alkylaryl group, an arylalkyl group, a cycloalkyl group, a cycloalkenyl group or a heterocyclic ring and is optionally substituted with one or more C1-C10 alkyl groups, C1-C10alkoxy groups, hydroxyl groups, cyano groups, carboxylate groups, halides, aryl groups, alkylaryl groups, arylalkyl groups, cycloalkyl groups, cycloalkenyl groups or heterocyclic rings.

Design and synthesis of small molecule glycerol 3-phosphate acyltransferase inhibitors

The incidence of obesity and other diseases associated with an increased triacylglycerol mass is growing rapidly, particularly in the United States. Glycerol 3-phosphate acyltransferase (GPAT) catalyzes the ratelimiting step of glycerolipid biosynthesis, the acylation of glycerol 3-phosphate with saturated long-chain acyl-CoAs. In an effort to produce small molecule inhibitors of this enzyme, a series of benzoic and phosphonic acids was designed and synthesized. In vitro testing of this series has led to the identification of several compounds, in particular 2-(nonylsulfonamido)benzoic acid (15g), possessing moderate GPAT inhibitory activity in an intact mitochondrial assay.

NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE and INFLAMMATORY DISEASES

The present invention relates to compounds of formula (I) that are inhibitors of PDElA, a phosphodiesterase that is involved in the modulation of the degradation of cartilage, joint degeneration and diseases involving such degradation and/or inflammation.

Base-free monosulfonylation of amines using tosyl or mesyl chloride in water

A mild and efficient procedure has been developed for the monosulfonylation of various amines using mesyl or tosyl chlorides in water at room temperature to afford the corresponding sulfonamides in high yields.

COX-1/COX-2 inhibitors based on the methanone moiety

This paper focuses on the synthesis and the in vitro testing of dual COX-1/COX-2 inhibitors. Starting from structures of non-steroidal anti-inflammatory drugs (NSAIDs) the diaryl methanone element was chosen as a lead. Modifications were carried out on this scaffold to obtain potent inhibitors of the COX enzymes. The N-(2-aroylphenyl)sulphonamides and -amides were studied in detail, and to consolidate the data evaluated the corresponding 3- and 4-regioisomers were also investigated. The potency and the enzyme selectivity were varied by structural modifications of the lead.